GAIA BioMedicine

Name

GAIA BioMedicine

Legal name

株式会社ガイアバイオメディシン

Website

https://gaia-biomed.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Cancer Cell Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

NK Cell Therapies (HLAAABAD)

Keywords

• Allogeneic cell therapy
• Cancer immunotherapy
• NK cell therapy
• Solid tumor treatment
• Biopharmaceutical development

Headquarters

HQ city

Fukuoka

HQ country

Japan

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Others

Revenue model

1. Investigational Product Revenue: As a clinical-stage biopharmaceutical company, GAIA BioMedicine does not currently have commercial revenue. The company is developing GAIA-102 and GAIA-151 for treatment of refractory solid tumors through clinical trials.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

GAIA BioMedicine develops allogeneic NK-cell-like cell therapies for refractory solid tumors using its proprietary GAIA NK-like cell platform. The lead investigational product GAIA-102 (WHO recommended INN: fulamleucel) is manufactured via the world's first mixed PBMC culture technology from multiple donors, achieving high-activity, high-infiltration phenotype without genetic modification and enabling fully off-the-shelf cryopreserved administration. The company is currently running investigator-initiated Phase I/II clinical trials for pediatric neuroblastoma, gastric/pancreatic cancer with peritoneal dissemination, and non-small cell lung cancer, with next-generation product GAIA-151 in preclinical development targeting 10,000 patients per year capacity.

Differentiator

Problem solved

Functional benefit

Products and services

• GAIA-102 (rINN: fulamleucel)
• AdoptCellR-NK Kit

Quantifiable outcome

• No dose-limiting toxicity observed in Phase I pediatric solid tumor trial (12 cases completed in Cohort A)
• +3 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Fukuoka Jisho (福岡地所)coreStrategic or Co-development Partner · 27 January 2026Partnership for establishing Cell Processing Center (CPC) at f-labs Kyushu University Hospital. Fukuoka Jisho constructed the facility and GAIA BioMedicine is establishing its proprietary CPC within it. Fukuoka Jisho invested in GAIA in 2023.
• Cellab Healthcare Service (Cellab HS)coreImplementation/ SI/ Consulting Partner · 21 June 2023Business agreement for production of GAIA-102. Cellab HS (wholly-owned subsidiary of DAI-DAN) received exclusive manufacturing rights for investigational products within Japan and non-exclusive license for commercial production. Press conference held at Ministry of Health, Labour and Welfare.
• TreeFrog TherapeuticscoreTechnology or Integration · 15 February 2023Collaboration for expansion of donor-derived NK-like cells using TreeFrog's biomimetic C-Stem technology platform. The partnership aims to enable expansion of NK-like immune cells in conventional stirred-tank bioreactors while maintaining desired phenotype, providing an alternative platform for large-scale GMP manufacturing.

Scale indicators9 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Nkarta Therapeutics: Clinical-stage biotech developing allogeneic NK cell therapies for hematologic malignancies and solid tumors. Most directly comparable as an allogeneic, off-the-shelf NK platform pursuing multiple solid tumor indications.
• Fate Therapeutics: iPSC-derived NK and T cell therapy programs for cancer, including off-the-shelf products. Highly comparable as a multi-product allogeneic cell therapy platform with focus on NK lineage.
• Century Therapeutics: Allogeneic iPSC-derived cell therapies (NK and T) engineered for solid tumors and hematologic malignancies. Direct peer as allogeneic platform with NK programs and explicit solid tumor focus.
• Caribou Biosciences: Clinical-stage company developing allogeneic CAR-NK and CAR-T cell therapies. Comparable as a gene-edited, allogeneic NK platform, although Caribou adds genetic modification where GAIA relies on culture technology alone.
• Shoreline Biosciences: iPSC-derived NK cell therapy developer partnering with major pharma (e.g., Kite) for allogeneic NK programs in oncology. Comparable as a next-generation allogeneic NK platform with similar scalability ambitions.
• GT Biopharma: Clinical-stage immuno-oncology company developing NK cell engagers and NK-based therapies for hematologic malignancies and solid tumors. Comparable NK-focused oncology platform.
• Allogene Therapeutics: Pioneer in allogeneic CAR-T cell therapy with multiple programs in solid tumors and hematologic cancers. Highly comparable as the benchmark allogeneic cell therapy platform, though focused on T cell rather than NK lineage.
• Atara Biotherapeutics: Developer of allogeneic T-cell and NK-cell therapies for oncology and autoimmune disease. Comparable as an allogeneic, off-the-shelf cell therapy platform with oncology focus.

Broad incumbents

• Adaptimmune: Clinical-stage cell therapy company developing engineered TCR-T therapies primarily for solid tumors. Comparable as a cell therapy platform targeting solid tumor indications, though uses autologous TCR-T rather than allogeneic NK.

Regional players

• Takeda Pharmaceutical: Japanese-headquartered global pharma with growing cell therapy investments (e.g., TAK-007 partnership with MD Anderson, acquisition of Maverick). Most relevant regional incumbent and potential acquirer/partner for Japanese cell therapy assets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/gaia-biomedicine-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GAIA BioMedicine